Compare Crispr Therapeutics AG (CRSP) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Equinor ASA — how do they compare? Crispr Therapeutics AG trades at $51.49 (market cap $4.97B), while Equinor ASA trades at $35.93 (market cap $83.20B). The key difference: Equinor ASA is far larger — about 16.7× Crispr Therapeutics AG's market cap, and Equinor ASA pays a 4.2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EQNR | |
|---|---|---|
Market Cap | $4.97B | $83.20B |
Sector | Health | Energy |
52-Week High | $76.78 | $42.40 |
52-Week Low | $44.34 | $22.41 |
Enterprise Value | $3.32B | $94.96B |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Equinor (EQNR) trades at $36.06, up 6.31% with a bullish technical outlook despite mixed earnings. The stock shows strong profitability with 37.45% gross margins and attractive valuation metrics including a P/E of 16.32 and EV/EBITDA of 2.37. Recent strategic moves include expanding Norwegian Continental Shelf operations through $410M Troll field investment and acquiring BP's Bay du Nord stake, positioning for production growth.
EQNR presents a balanced opportunity with solid fundamentals and strategic growth initiatives, though declining revenue and net income trends warrant monitoring. Analyst sentiment is mixed with 30% buy ratings, while technical indicators suggest near-term strength. Key risks include volatile energy prices and execution challenges in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
